Tarsus Pharmaceuticals is making a splash with Xdemvy, an eye drop that kills the demodex mites that cause inflammation and ...

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03 ...

Tarsus Pharmaceuticals, Inc. (TARS) shares ended the last trading session 10.6% higher at $43.87. The jump came on an impressive volume with a higher-than-average number of shares changing hands ...

This renewed interest in DB presented Tarsus with an opportunity to reup its efforts to combat a pressing yet often overlooked health condition.

Tarsus Pharmaceuticals (NASDAQ:TARS) reported positive topline results from a Phase 2a proof-of-concept study of its product TP-05 in the prevention of Lyme disease. The study evaluated TP-05’s ...

Tarsus Pharmaceuticals' lead asset, lotilaner (XDEMVY), has shown strong market performance, achieving a 75% stock increase since August despite initial doubts. Lotilaner, approved for Demodex ...

Allspring Global Investments Holdings LLC cut its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Bleakley Financial Group LLC bought a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) in ...

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...